BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 15, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Neobiosis to advance Vixome for post-COVID syndrome
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Immune
Neobiosis to advance Vixome for post-COVID syndrome
June 13, 2023
No Comments
Neobiosis LLC has received FDA clearance of its IND application for Vixome for the treatment of post-COVID syndrome, or long-haul COVID...
BioWorld Science
Immune
Infection
Inflammatory
Coronavirus
FDA
IND